Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (Nasdaq: RIGL) on October 3, 2025 announced inducement equity awards under NASDAQ Listing Rule 5635(c)(4).
The company granted 41,138 stock options and 27,475 restricted stock units to 14 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the compensation committee under Rigel's Inducement Plan.
Rigel Pharmaceuticals (Nasdaq: RIGL) il 3 ottobre 2025 ha annunciato premi azionari di incentivo ai sensi della Regola 5635(c)(4) della quotazione NASDAQ.
L’azienda ha concesso 41.138 opzioni su azioni e 27.475 unità azionarie soggette a restrizioni a 14 dipendenti non dirigenti. I premi maturano in quattro anni con una cliff di un anno. Le assegnazioni sono state approvate dal comitato di retribuzione nell’ambito del Rigel Inducement Plan.
Rigel Pharmaceuticals (Nasdaq: RIGL) el 3 de octubre de 2025 anunció premios de inducción bajo la Regla 5635(c)(4) de NASDAQ Listing.
La empresa concedió 41.138 opciones sobre acciones y 27.475 unidades de acciones restringidas (RSU) a 14 empleados no ejecutivos. Los premios vencen (se consolidan) a lo largo de cuatro años con una cláusula de un año. Las concesiones fueron aprobadas por el comité de compensación conforme al Plan de Inducción de Rigel.
Rigel Pharmaceuticals (나스닥: RIGL)는 2025년 10월 3일 NASDAQ 상장 규칙 5635(c)(4)에 따른 유인 주식 보상을 발표했습니다.
회사는 41,138주식매수선택권과 27,475 제한 주식단위(RSU)를 14명의 비임원 직원에게 수여했습니다. 보상은 4년 동안 가속 vesting되며 1년 cliff가 적용됩니다. 수여는 Rigel의 Inducement Plan에 따라 보상위원회에서 승인되었습니다.
Rigel Pharmaceuticals (Nasdaq : RIGL) le 3 octobre 2025 a annoncé des attributions d’actions d’incitation en vertu de la règle 5635(c)(4) de la cotation NASDAQ.
L’entreprise a accordé 41 138 options d’achat d’actions et 27 475 unités d’actions restreintes (RSU) à 14 employés non cadres. Les attributions se vestent sur quatre ans avec une période de cliff d’un an. Les attributions ont été approuvées par le comité de rémunération dans le cadre du Rigel Inducement Plan.
Rigel Pharmaceuticals (Nasdaq: RIGL) am 3. Oktober 2025 kündigte Anreiz-Aktienzuteilungen gemäß NASDAQ Listing Rule 5635(c)(4) an.
Das Unternehmen gewährte 41.138 Aktienoptionen und 27.475 Restricted Stock Units (RSU) an 14 nicht führende Mitarbeitende. Die Zuteilungen vesten über vier Jahre mit einer einjährigen Cliff-Periode. Die Zuteilungen wurden vom Vergütungsausschuss gemäß Rigels Inducement Plan genehmigt.
Rigel Pharmaceuticals (Nasdaq: RIGL) في 3 أكتوبر 2025 أعلن عن منح أسهم تحفيزية بموجب القاعدة 5635(c)(4) لقائمة ناسداك.
منحت الشركة 41,138 خياراً على أسهم و 27,475 وحدة أسهم مقيدة إلى 14 موظفاً غير تنفيذي. تتأتى الاستحقاقات خلال أربعة سنوات مع فاصل استحقاق لمدة سنة. تمت الموافقة على المنح من قبل لجنة التعويض وفق خطّة التحفيز لدى Rigel.
Rigel Pharmaceuticals（纳斯达克：RIGL） 于 2025年10月3日 根据 NASDAQ Listing Rule 5635(c)(4) 宣布了诱导性股票奖励。
公司向 14名非高级管理人员 授予 41,138份股票期权 和 27,475份限制性股票单位（RSU）。奖励在 四年内归属，设有一年悬崖期。授予经 Rigel 的诱导计划获薪酬委员会批准。
- None.
- None.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302574356.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
What did Rigel (RIGL) announce on October 3, 2025 about inducement grants?
How many employees received inducement awards from Rigel (RIGL) on Oct 3, 2025?
What is the vesting schedule for Rigel's (RIGL) Oct 2025 inducement grants?
Do Rigel's (RIGL) Oct 3, 2025 inducement grants require Nasdaq rule disclosure?
What equity types did Rigel (RIGL) grant in the Oct 2025 inducement announcement?
Will Rigel's (RIGL) Oct 2025 inducement grants immediately dilute existing shareholders?
